Each filer's latest filing for 254604101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
12.8% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 12.8% | |||
| Abigail P. Johnson | 12.8% | |||
|
AI Dmi LLC
13D/A
|
6.6% |
10/26/2026
Event 10/22/2026
|
||
| AI Dmi LLC | 6.6% | |||
| Access Industries Holdings LLC | 6.6% | |||
| Access Industries Management, LLC | 6.6% | |||
| Len Blavatnik | 6.6% | |||
|
RA Capital Management, L.P.
13G
|
5.9% |
1/7/2026
Event 12/30/2025
|
||
| RA Capital Management, L.P. | 5.9% | |||
| Peter Kolchinsky | 5.9% | |||
| Rajeev Shah | 5.9% | |||
| RA Capital Healthcare Fund, L.P. | 5.9% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
|
Orbimed Advisors LLC
13D/A
|
4.5% |
3/12/2025
Event 3/10/2025
|
||
| Orbimed Advisors LLC | 4.5% | |||
| Orbimed Capital GP VI LLC | 1.5% | |||
| OrbiMed Capital GP VIII LLC | 2.4% | |||
| OrbiMed Genesis GP LLC | 0.6% | |||
|
Wellington Management Group LLP
13G/A
|
4.1% |
8/12/2025
Event 6/30/2025
|
||
| Wellington Management Group LLP | 4.1% | |||
| Wellington Group Holdings LLP | 4.1% | |||
| Wellington Investment Advisors Holdings LLP | 4.1% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
3.5% |
5/15/2025
Event 3/31/2025
|
||
| Paradigm BioCapital Advisors LP | 3.5% | |||
| Paradigm BioCapital Advisors GP LLC | 3.5% | |||
| Senai Asefaw, M.D. | 3.5% | |||
| Paradigm BioCapital International Fund Ltd. | 3.1% | |||
| Bain Capital Life Sciences Opportunities III, LP 13G/A | 3.3% |
2/14/2025
Event 12/31/2024
|
||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
3.0% |
8/14/2025
Event 6/30/2025
|
||
| Frazier Life Sciences Public Fund, L.P. | 3.0% | |||
| FHMLSP, L.P. | 3.0% | |||
| FHMLSP, L.L.C. | 3.0% | |||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.9% | |||
| FHMLSP Overage, L.P. | 0.9% | |||
| FHMLSP Overage, L.L.C. | 0.9% | |||
| Frazier Life Sciences X, L.P. | 0.2% | |||
| FHMLS X, L.P. | 0.2% | |||
| FHMLS X, L.L.C. | 0.2% | |||
| Frazier Life Sciences XI, L.P. | 0.8% | |||
| FHMLS XI, L.P. | 0.8% | |||
| FHMLS XI, L.L.C. | 0.8% | |||
| James N. Topper | 0.2% | |||
| Patrick J. Heron | 0.2% | |||
| Albert Cha | 0% | |||
| James Brush | 0% | |||
| Daniel Estes | 0% | |||
|
Atlas Venture Fund X, L.P.
13D/A
|
2.2% |
12/17/2025
Event 12/12/2025
|
||
| Atlas Venture Fund X, L.P. | 2.2% | |||
| Atlas Venture Associates X, L.P. | 2.2% | |||
| Atlas Venture Associates X, LLC | 2.2% | |||
| Atlas Venture Fund XII, L.P. | 0% | |||
| Atlas Venture Associates XII, L.P. | 0% | |||
| Atlas Venture Associates XII, LLC | 0% | |||
| Atlas Venture Opportunity Fund I, L.P. | 0.9% | |||
| Atlas Venture Associates Opportunity I, L.P. | 0.9% | |||
| Atlas Venture Associates Opportunity I, LLC | 0.9% | |||
| Atlas Venture Opportunity Fund II, L.P. | 0.9% | |||
| Atlas Venture Associates Opportunity II, LP | 0.9% | |||
| Atlas Venture Associates Opportunity II, LLC | 0.9% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 240 | 43.6 M | $2.86B |
| 2026 Q2 | 224 | 42.8 M | $3.13B |
| 2026 Q1 | 208 | 41.9 M | $2.67B |
| 2025 Q4 | 202 | 38.3 M | $3.04B |
| 2025 Q3 | 173 | 34.2 M | $2.26B |
| 2025 Q2 | 155 | 34.1 M | $1.80B |
| 2025 Q1 | 161 | 33.2 M | $1.65B |
| 2024 Q4 | 156 | 26.6 M | $1.68B |
| 2024 Q3 | 134 | 27.4 M | $1.35B |
| 2024 Q2 | 124 | 27.6 M | $1.24B |
| 2024 Q1 | 137 | 22.3 M | $1.38B |
| 2023 Q4 | 113 | 20.2 M | $1.17B |
| 2023 Q3 | 94 | 19.9 M | $934M |
| 2023 Q2 | 92 | 19.1 M | $849M |
| 2023 Q1 | 46 | 14.6 M | $310M |
| 2022 Q4 | 36 | 11.4 M | $216M |